JP2011103891A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011103891A5 JP2011103891A5 JP2011010411A JP2011010411A JP2011103891A5 JP 2011103891 A5 JP2011103891 A5 JP 2011103891A5 JP 2011010411 A JP2011010411 A JP 2011010411A JP 2011010411 A JP2011010411 A JP 2011010411A JP 2011103891 A5 JP2011103891 A5 JP 2011103891A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- seq
- acid residues
- tumor cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004881 tumor cell Anatomy 0.000 claims 24
- 125000000539 amino acid group Chemical group 0.000 claims 16
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 10
- 229920001184 polypeptide Polymers 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 101150092419 STRA6 gene Proteins 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 7
- 229940127089 cytotoxic agent Drugs 0.000 claims 7
- 150000004492 retinoid derivatives Chemical class 0.000 claims 7
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000002254 cytotoxic agent Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 101100156752 Caenorhabditis elegans cwn-1 gene Proteins 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 102000052547 Wnt-1 Human genes 0.000 claims 3
- 108700020987 Wnt-1 Proteins 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims 3
- 208000023965 endometrium neoplasm Diseases 0.000 claims 3
- 230000009395 genetic defect Effects 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 208000037841 lung tumor Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 230000037361 pathway Effects 0.000 claims 3
- 208000028591 pheochromocytoma Diseases 0.000 claims 3
- 102000015735 Beta-catenin Human genes 0.000 claims 2
- 108060000903 Beta-catenin Proteins 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 239000012190 activator Substances 0.000 claims 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000012010 growth Effects 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 229930002330 retinoic acid Natural products 0.000 claims 2
- 229960001727 tretinoin Drugs 0.000 claims 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000004565 tumor cell growth Effects 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17584900P | 2000-01-13 | 2000-01-13 | |
| US60/175,849 | 2000-01-13 | ||
| US19708900P | 2000-04-14 | 2000-04-14 | |
| US60/197,089 | 2000-04-14 | ||
| US22891400P | 2000-08-29 | 2000-08-29 | |
| US60/228,914 | 2000-08-29 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001551209A Division JP2003519491A (ja) | 2000-01-13 | 2001-01-11 | 新規なｓｔｒａ６ポリペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011103891A JP2011103891A (ja) | 2011-06-02 |
| JP2011103891A5 true JP2011103891A5 (enExample) | 2012-11-29 |
| JP5701624B2 JP5701624B2 (ja) | 2015-04-15 |
Family
ID=27390600
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001551209A Pending JP2003519491A (ja) | 2000-01-13 | 2001-01-11 | 新規なｓｔｒａ６ポリペプチド |
| JP2011010411A Expired - Fee Related JP5701624B2 (ja) | 2000-01-13 | 2011-01-21 | 新規なｓｔｒａ６ポリペプチド |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001551209A Pending JP2003519491A (ja) | 2000-01-13 | 2001-01-11 | 新規なｓｔｒａ６ポリペプチド |
Country Status (15)
| Country | Link |
|---|---|
| US (7) | US7173115B2 (enExample) |
| EP (1) | EP1246917B1 (enExample) |
| JP (2) | JP2003519491A (enExample) |
| KR (2) | KR20080006002A (enExample) |
| CN (2) | CN1425066B (enExample) |
| AT (1) | ATE424457T1 (enExample) |
| AU (2) | AU785055B2 (enExample) |
| CA (1) | CA2397207C (enExample) |
| DE (1) | DE60137829D1 (enExample) |
| DK (1) | DK1246917T3 (enExample) |
| ES (1) | ES2323220T3 (enExample) |
| IL (2) | IL150676A0 (enExample) |
| NZ (1) | NZ520095A (enExample) |
| PT (1) | PT1246917E (enExample) |
| WO (1) | WO2001051635A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1425066B (zh) * | 2000-01-13 | 2010-05-26 | 杰南技术公司 | 新的stra6多肽 |
| CA2406527A1 (en) * | 2000-03-23 | 2002-10-03 | Curagen Corporation | Novel human stras-like protein and nucleic acids encoding the same |
| CN1339489A (zh) * | 2000-08-23 | 2002-03-13 | 上海博德基因开发有限公司 | 一种新的多肽——人视黄酸效应蛋白53.57和编码这种多肽的多核苷酸 |
| ATE453718T1 (de) * | 2000-08-29 | 2010-01-15 | Genentech Inc | Verfahren zur verbesserung von krebstherapie |
| AU2002308557A1 (en) * | 2001-05-01 | 2002-11-11 | The Regents Of The University Of California | Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas |
| US7081340B2 (en) * | 2002-03-13 | 2006-07-25 | Genomic Health, Inc. | Gene expression profiling in biopsied tumor tissues |
| US7666627B2 (en) * | 2002-08-08 | 2010-02-23 | Targetex Kft. | Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof |
| JP2006508939A (ja) * | 2002-10-29 | 2006-03-16 | エンジーン， インコーポレイテッド | 癌処置のための組成物 |
| WO2004098502A2 (en) * | 2003-04-30 | 2004-11-18 | Centocor, Inc. | Cngh0010 specific polynucleotides, polypeptides, antibodies, compositions, methods and uses. |
| US7780721B2 (en) * | 2004-09-01 | 2010-08-24 | C. R. Bard, Inc. | Stent and method for manufacturing the stent |
| US20090048196A1 (en) * | 2007-01-18 | 2009-02-19 | The Regents Of The University Of California | Membrane receptor for retinol binding protein mediates cellular uptake of vitamin A, methods of use and compositions |
| WO2010008427A1 (en) * | 2008-04-11 | 2010-01-21 | Ludwig Institute For Cancer Research Ltd. | Tryptophan catabolism in cancer treatment and diagnosis |
| WO2010151793A1 (en) * | 2009-06-26 | 2010-12-29 | Five Prime Therapeutics, Inc. | Therapeutic antibody target validation and screening in vivo |
| US9551034B2 (en) | 2010-01-11 | 2017-01-24 | Genomic Health, Inc. | Method to use gene expression to determine likelihood of clinical outcome of renal cancer |
| CA3081061C (en) * | 2010-07-27 | 2023-01-03 | Genomic Health, Inc. | Method for using expression of klk2 to determine prognosis of prostate cancer |
| MX351626B (es) | 2012-01-31 | 2017-10-23 | Genomic Health Inc | Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata. |
| BR112014019741A2 (pt) | 2012-02-11 | 2020-12-22 | Genentech, Inc | Usos de um antagonista da via wnt, uso de uma terapia anticâncer, método de identificação de um indivíduo com câncer, métodos para prever, método de inibição da proliferação de uma célula de câncer, uso de um antagonista da translocação de r-spondina e antagonista da translocação de r-spondina isolado |
| US10181008B2 (en) | 2013-05-30 | 2019-01-15 | Genomic Health, Inc. | Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer |
| EP3636661A1 (en) * | 2018-10-12 | 2020-04-15 | Bioc3 | Phosphate translocator |
| CN116287211B (zh) * | 2023-03-24 | 2025-10-10 | 中国医学科学院北京协和医院 | STRA6和miR-1249-5p在制备诊断子宫腺肌症的产品中的应用 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4444545A (en) * | 1982-04-08 | 1984-04-24 | Sanders David F | Pump control system |
| US4943529A (en) | 1982-05-19 | 1990-07-24 | Gist-Brocades Nv | Kluyveromyces as a host strain |
| US4485054A (en) * | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
| US4870009A (en) | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
| AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| AU3145184A (en) | 1983-08-16 | 1985-02-21 | Zymogenetics Inc. | High expression of foreign genes in schizosaccharomyces pombe |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| US4676417A (en) * | 1986-04-14 | 1987-06-30 | Richard Hirschkoff | Ski carrier |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US5010182A (en) | 1987-07-28 | 1991-04-23 | Chiron Corporation | DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US4997852A (en) | 1987-08-26 | 1991-03-05 | Ohio State University Research Foundation | Method and composition for achieving cancer chemopreventive and chemotherapeutic activity |
| IL87737A (en) | 1987-09-11 | 1993-08-18 | Genentech Inc | Method for culturing polypeptide factor dependent vertebrate recombinant cells |
| JPH04501201A (ja) | 1987-12-21 | 1992-03-05 | ジ・アップジョン・カンパニー | 発芽植物種子類のアグロバクテリウム媒介形質転換 |
| SE8802525L (sv) | 1988-07-06 | 1990-01-07 | Fmg Filipstad Ab | Stol |
| AU4005289A (en) | 1988-08-25 | 1990-03-01 | Smithkline Beecham Corporation | Recombinant saccharomyces |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5009772A (en) | 1989-02-27 | 1991-04-23 | Kerr-Mcgee Corporation | Solvent extraction process |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0394538B1 (en) | 1989-04-28 | 1996-10-16 | Rhein Biotech Gesellschaft Für Neue Biotechnologische Prozesse Und Produkte Mbh | A yeast cell of the genus schwanniomyces |
| WO1990013641A1 (en) | 1989-05-10 | 1990-11-15 | Sloan-Kettering Institute For Cancer Research | Stably transformed eucaryotic cells comprising a foreign transcribable dna under the control of a pol iii promoter |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP0739904A1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| FR2649120B1 (fr) | 1989-06-30 | 1994-01-28 | Cayla | Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede |
| WO1991004753A1 (en) | 1989-10-02 | 1991-04-18 | Cetus Corporation | Conjugates of antisense oligonucleotides and therapeutic uses thereof |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| US5731167A (en) | 1992-01-17 | 1998-03-24 | The United States Of America As Represented By The Department Of Health And Human Services | Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy |
| US5756448A (en) | 1992-02-26 | 1998-05-26 | The General Hospital Corporation | Constitute activator of retinoid (CAR) receptor polypeptides |
| WO1993018186A1 (en) | 1992-03-04 | 1993-09-16 | The Regents Of The University Of California | Comparative genomic hybridization (cgh) |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| JPH08503950A (ja) | 1992-12-02 | 1996-04-30 | アルカーメス・コントロールド・セラピユーテイクス・インコーポレーテツド | 徐放性成長ホルモン含有マイクロスフェア |
| US5547947A (en) * | 1993-03-11 | 1996-08-20 | Hoffmann-La Roche Inc. | Methods of treatment |
| PT616812E (pt) | 1993-03-24 | 2000-04-28 | Berlex Biosciences | Combinacao de compostos anti-hormonais e moleculas de ligacao no tratamento do cancro |
| US5681860A (en) | 1993-09-21 | 1997-10-28 | The Trustees Of Columbia University In The City Of New York | Method of increasing expression of HLA, cell surface and TAA antigens of cells using 3-(N-acetylamino)-5-(N-decyl-N-methylamino)-benzyl alcohol |
| EP1002529A1 (en) | 1994-09-09 | 2000-05-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation containing a metal salt of a peptide |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6316007B1 (en) | 1995-04-04 | 2001-11-13 | Wound Healing Of Oklahoma | Combined physical and immunotherapy for cancer |
| SK281571B6 (sk) | 1995-06-07 | 2001-05-10 | Alkermes Controlled Therapeutics, Inc. | Prostriedok na trvalé uvoľňovanie ľudského rastového hormónu |
| ZA965368B (en) | 1995-07-14 | 1997-01-14 | Novo Nordisk As | A pharmaceutical formulation |
| US5871697A (en) * | 1995-10-24 | 1999-02-16 | Curagen Corporation | Method and apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing |
| US6458939B1 (en) | 1996-03-15 | 2002-10-01 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation |
| US6525174B1 (en) * | 1997-06-06 | 2003-02-25 | Human Genome Sciences, Inc. | Precerebellin-like protein |
| EP1039801A4 (en) * | 1997-06-06 | 2003-03-26 | Human Genome Sciences Inc | 207 HUMAN SECRETED PROTEINS |
| EP1206536A2 (en) | 1999-08-17 | 2002-05-22 | Sagami Chemical Research Center | HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS |
| CN1425066B (zh) * | 2000-01-13 | 2010-05-26 | 杰南技术公司 | 新的stra6多肽 |
| CA2406527A1 (en) | 2000-03-23 | 2002-10-03 | Curagen Corporation | Novel human stras-like protein and nucleic acids encoding the same |
| US20030100710A1 (en) | 2000-06-05 | 2003-05-29 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20030187201A1 (en) | 2000-09-15 | 2003-10-02 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US7157558B2 (en) | 2001-06-01 | 2007-01-02 | Genentech, Inc. | Polypeptide encoded by a polynucleotide overexpresses in tumors |
-
2001
- 2001-01-11 CN CN018064965A patent/CN1425066B/zh not_active Expired - Fee Related
- 2001-01-11 CA CA2397207A patent/CA2397207C/en not_active Expired - Fee Related
- 2001-01-11 KR KR1020077028133A patent/KR20080006002A/ko not_active Ceased
- 2001-01-11 DK DK01904821T patent/DK1246917T3/da active
- 2001-01-11 US US09/759,056 patent/US7173115B2/en not_active Expired - Fee Related
- 2001-01-11 EP EP01904821A patent/EP1246917B1/en not_active Expired - Lifetime
- 2001-01-11 PT PT01904821T patent/PT1246917E/pt unknown
- 2001-01-11 ES ES01904821T patent/ES2323220T3/es not_active Expired - Lifetime
- 2001-01-11 AT AT01904821T patent/ATE424457T1/de active
- 2001-01-11 WO PCT/US2001/000847 patent/WO2001051635A2/en not_active Ceased
- 2001-01-11 NZ NZ520095A patent/NZ520095A/en not_active IP Right Cessation
- 2001-01-11 CN CN200910147020A patent/CN101643733A/zh active Pending
- 2001-01-11 AU AU32768/01A patent/AU785055B2/en not_active Ceased
- 2001-01-11 JP JP2001551209A patent/JP2003519491A/ja active Pending
- 2001-01-11 IL IL15067601A patent/IL150676A0/xx unknown
- 2001-01-11 DE DE60137829T patent/DE60137829D1/de not_active Expired - Lifetime
- 2001-07-10 US US09/901,812 patent/US20020173461A1/en not_active Abandoned
-
2002
- 2002-07-10 IL IL150676A patent/IL150676A/en not_active IP Right Cessation
- 2002-07-12 KR KR1020027009049A patent/KR100929057B1/ko not_active Expired - Fee Related
-
2006
- 2006-05-22 US US11/438,488 patent/US7741439B2/en not_active Expired - Fee Related
- 2006-07-18 US US11/458,181 patent/US7939650B2/en not_active Expired - Fee Related
- 2006-07-18 US US11/458,237 patent/US20070025998A1/en not_active Abandoned
- 2006-11-24 AU AU2006241374A patent/AU2006241374B2/en not_active Ceased
-
2007
- 2007-10-31 US US11/932,861 patent/US7855278B2/en not_active Expired - Fee Related
-
2010
- 2010-11-11 US US12/944,519 patent/US20110171238A1/en not_active Abandoned
-
2011
- 2011-01-21 JP JP2011010411A patent/JP5701624B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2899954T3 (es) | Métodos para tratar el cáncer de piel mediante la administración de un inhibidor de PD-1 | |
| ES2931337T3 (es) | Un método para la identificación de combinaciones de inmunoterapia-fármacos usando un enfoque de red | |
| Trivedi et al. | Trailing TRAIL resistance: novel targets for TRAIL sensitization in cancer cells | |
| JP2026053616A (ja) | 癌の治療のためのクローディン１８．２に対する抗体を含む治療法 | |
| US20210069147A1 (en) | Pharmaceutical combination and uses thereof | |
| MX348577B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| HK1259190A1 (zh) | 嵌合抗原受体相关的方法和组合物 | |
| RU2014138038A (ru) | Фармацевтическая композиция для лечения профилактики рака | |
| CN111132696B (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| CN117222663A (zh) | 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法 | |
| MX348578B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| JP2012102122A5 (enExample) | ||
| RU2012137503A (ru) | Лекарственный препарат для лечения и/или профилактики рака | |
| JP7304595B2 (ja) | ｕＰＡＲＡＰを標的にする抗体薬物複合体 | |
| Tagliamonte et al. | Potentiating cancer vaccine efficacy in liver cancer | |
| Yu et al. | Synergistic antitumor effects of 9.2. 27-PE38KDEL and ABT-737 in primary and metastatic brain tumors | |
| JP2023011902A (ja) | Ｐｄ－１阻害剤を投与することにより子宮頸がんを処置する方法 | |
| WO2021182572A1 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| Bossi et al. | Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer | |
| WO2021182571A1 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| US20240374644A1 (en) | Herv-k antibody therapeutics | |
| Wang et al. | Rab GTPase 21 mediates caerulin-induced TRAF3-MKK3-p38 activation and acute pancreatitis response | |
| WO2018209017A1 (en) | Cancer treatment with a cxcl12 signaling inhibitor and an immune checkpoint inhibitor | |
| CN117693363A (zh) | 用于癌的治疗和/或预防的药品 | |
| JP7504106B2 (ja) | がんの処置のための組合せ物 |